Advertisement

Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Posted: 01/31/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Tebentafusp-tebn is the first bispecific T-cell engager to receive regulatory approval from the FDA to treat a solid tumor. Tebentafusp consists of:

Choose 1

A
An affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100 (gp100)-positive cells
B
An affinity-enhanced T-cell receptor fused to an anti-CD16 effector that can redirect T cells to target gp100-positive cells
C
An affinity-enhanced T-cell receptor fused to an anti-TNF-α effector that can redirect T cells to target melanoma antigen (MART)-1–positive cells
D
An affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target MART-1–positive cells

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage